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Compared with 
hydrochlorothiazide, 
chlorthalidone reduces 
cardiovascular events in  
patients with hypertension
Dorsch et al., Hypertension 2011; 57: 689–694; doi:10.1161/
HYPERTENSIONAHA.110.161505
A large body of evidence indicates that reduction in extracel-
lular fluid volume is needed to effectively lower blood pressure 
in most patients with hypertension. This is almost universally 
accomplished by the use of diuretics, particularly thiazide-type 
diuretics, and most professional bodies recommend these drugs 
as a primary choice for the treatment of hypertension. Indeed, 
in the case of uncomplicated hypertension, without the pres-
ence of comorbid conditions that would benefit from other types 
of antihypertensive drugs, thiazides are considered one of the 
initial agents to use. If not used as initial therapy, thiazides are 
recommended as the next agent to be added to existing therapy, 
should more effective treatment be needed. Clinicians have sev-
eral options when prescribing a thiazide-type diuretic; by far the 
most commonly prescribed is hydrochlorothiazide (HCTZ), 
followed by chlorthalidone (CTD), but other thiazides include 
chlorothiazide, metolazone, and indapamide. The choice between 
HCTZ and CTD for the treatment of hypertension has stimulated 
a lively debate, because a study suggested that, when compared 
with HCTZ, CTD has superior 24-hour blood pressure control, 
but other studies found comparable efficacy. To evaluate the 
effects of CTD compared with HCTZ on rates of cardiovascular 
events (CVEs), Dorsch et al. performed a retrospective observa-
tional cohort study using the Multiple Risk Factor Intervention 
Trial (MRFIT) data set. This trial was a cardiovascular primary 
prevention trial whose participants were men 35–57 years of age 
enrolled and followed beginning in 1973. CVEs were measured 
yearly, and time to event was assessed by Cox regression. Systolic 
blood pressure, total cholesterol, low-density and high-density 
lipoprotein cholesterol, triglyceride, potassium, glucose, and uric 
acid were measured yearly. The difference between groups was 
evaluated by repeated-measures mixed modeling, and each model 
was adjusted for predictors of each variable. CVEs were signifi-
cantly lower in those on CTD and those on HCTZ compared with 
those who took neither drug. When the two drugs were compared, 
CTD had significantly fewer CVEs than HCTZ (Figure). Patients 
taking CTD had significantly lower systolic blood pressure, total 
cholesterol, low-density lipoprotein, and potassium and higher 
uric acid over time than those taking HCTZ.
In conclusion, both HCTZ and CTD reduce CVEs compared 
with neither drug, but CTD reduced CVEs more than HCTZ, 
supporting the suggestion that CTD may be the preferred thia zide-
type diuretic for patients with hypertension.
Juan Oliver
The safety of combining 
angiotensin-converting enzyme 
inhibitors with angiotensin  
receptor blockers in elderly 
patients: a population-based 
longitudinal analysis
McAlister et al., CMAJ 2011; 183: 655–662; doi:10.1503/cmaj.101333
Renin–angiotensin system combination therapy with concur-
rent use of angiotensin-converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers confers additional benefits over the 
use of either agent alone for certain patients who have diabetic 
nephropathy or advanced systolic dysfunction of the left ventricle. 
Randomized controlled trials have reported an increased risk of 
renal dysfunction among patients given combination therapy com-
pared with those given monotherapy. McAlister et al. conducted a 
population-based longitudinal analysis using linked administrative 
and laboratory data for elderly patients who were new users of an 
ACE inhibitor, an angiotensin receptor blocker, or a combination 
of both medications. Of the 32,312 new users of either medica-
tion (mean age, 76.1 years; median creatinine level, 92 mmol/l), 
1750 received combination therapy. However, 1512 of the patients 
who were given combination therapy did not have trial-established 
indications such as heart failure or proteinuria. Renal dysfunction 
was more common among patients given combination therapy (5.2 
(95% CI, 3.4–7.9) events per 1000 patients per month) than among 
patients given monotherapy (2.4 (95% CI, 2.2–2.7) events per 1000 
patients per month) (adjusted hazard ratio (HR), 2.36 (95% CI, 
1.51–3.71)). Hyperkalemia was also more common among patients 
given combination therapy (2.5 (95% CI, 1.4–4.3) events per 1000 
patients per month) than among patients given monotherapy (0.9 
(95% CI, 0.8–1.0) events per 1000 patients per month) (adjusted 
HR, 2.42 (95% CI, 1.36–4.32)). Most patients took combination 
Adjusted event-free probability of cardiovascular events. The hazard 
ratio (HR) was estimated by the Cox model. Adjusted estimates were 
controlled for confounding factors.
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therapy for only a short time, with a median 3 months before 
at least one agent was stopped. The use of combination therapy 
among elderly patients in clinical practice seems to be associated 
with increased risks of adverse renal outcomes and hyperkalemia 
compared with monotherapy. The most striking findings were that 
combination therapy was commonly prescribed for patients who 
did not have the trial-proven indications and that it was frequently 
stopped after only a few months, even when hyperkalemia or renal 
dysfunction did not occur.
Although this well-designed study has some limitations, such 
as the prescription dispensations to define drug use, the relatively 
short duration of the observation, and the fact that the author 
did not evaluate whether patients who stopped taking their 
medication(s) subsequently restarted, the findings confirm what 
earlier randomized clinical trials have already mentioned.
Marc De Broe
Distinct macrophage phenotypes 
contribute to kidney injury and repair
Lee et al., J Am Soc Nephrol 2011; 22: 317–326; doi:10.1681/ASN.2009060615
In the early phase of acute ischemic kidney injury, the tubular-cell 
necrosis and apoptosis are accompanied by an inflammatory-cell 
infiltrate. It has been proposed that the early infiltrate contributes 
to the tissue injury, whereas in later phases, some of the infiltrat-
ing leukocytes contribute to the healing process. This process 
could be the result of the involvement of different macrophage 
phenotypes, termed M1 and M2 on the basis of the expression of 
different marker molecules. Lee et al. now convincingly show that 
iNos-positive proinflammatory (M1) macrophages are recruited 
into the kidney in the first 48 hours after ischemia/reperfusion 
injury, whereas arginase 1- and mannose receptor-positive, non-
inflammatory (M2) macrophages predominate at later time 
points. Depletion of macrophages before ischemia/reperfusion 
diminished kidney injury, whereas depletion at 3–5 days after 
injury slowed tubular-cell proliferation and repair. Adoptive trans-
fer of ex vivo interferon-g-stimulated, bone marrow-derived M1 
macrophages into macrophage-depleted mice at the time of kidney 
reperfusion restored injury to the level seen without macrophage 
depletion, suggesting that proinflammatory macrophages worsen 
kidney damage. In contrast, the appearance of macrophages with 
the M2 phenotype correlated with the repair phase. In vitro stud-
ies showed that interferon-g-stimulated, proinflammatory M1 
macrophages start expressing markers of M2 macrophages when 
cocultured with renal tubular cells. Moreover, interleukin-4-
stimulated macrophages with an M2 phenotype promoted renal 
tubular-cell proliferation. Finally, tracking fluorescently labeled 
M1 macrophages that were injected after injury switched to an 
M2 phenotype during kidney repair. Taken together, these stud-
ies show that, during renal injury and repair, macrophages can 
undergo a switch from a proinflammatory to a trophic phenotype 
that supports the transition from tubule injury to repair.
These studies confirm that macrophages are highly dynamic and 
plastic and can switch from an M1 to an M2 phenotype depending 
on the environment. Identifying the molecular factors influencing 
the different phenotypes should show us how to influence the bal-
ance from a proinflammatory to a healing intrarenal environment 
in order to reduce renal damage.
Detlef Schlöndorff
Randomized trial of stents versus 
bypass surgery for left main 
coronary artery disease
Park et al., N Engl J Med advance online publication, 4 April 2011, doi:10.1056/
NEJMoa1100452
Patients with chronic kidney disease and end-stage renal dis-
ease have a higher prevalence of coronary artery disease (CAD) 
than is seen in the general population. Observational studies 
prior to the advent of drug-eluting stents suggest a benefit from 
coronary artery bypass grafting (CABG). However, this benefit 
does not appear to be as significant in observational studies that 
incorporate eras in which drug-eluting stents were more widely 
used. The PRECOMBAT trial randomized 600 adults with newly 
diagnosed stenosis of more than 50% of the left main artery who 
were candidates for both interventions to undergo percutane-
ous coronary intervention (PCI) with sirolimus-eluting stents or 
CABG. All patients undergoing PCI but not CABG were asked to 
undertake follow-up angiography at 8–10 months after the proce-
dure. The primary end point was a composite of all-cause death, 
myocardial infarction, stroke, and ischemia-driven target-vessel 
revascularization. In comparison with patients with chronic kid-
ney disease and end-stage renal disease, the enrolled patients 
had a lower body mass index but were similar in the prevalence 
of diabetes and hypertension. At 12 months, 26 patients in the 
PCI arm and 20 patients in the CABG arm experienced an end 
point (8.7% versus 6.7%; absolute risk difference, 2.0%; 95% CI, 
–1.6 to 5.6), consistent with the non-inferior hypothesis. Dur-
ing the subsequent year, no differences were seen in the rates 
of the primary end point or any of its components, except for 
ischemia-driven target-vessel revascularization. Target-vessel 
revascularization was twice as likely in patients who underwent 
PCI as compared with CABG (HR, 2.18 (95% CI, 1.10–4.32)). 
There were no significant differences in the primary end point 
among multiple subgroups based on demographic and clinical 
characteristics. However, among patients with progressively less 
CAD, the point estimate progressively decreased favoring PCI. 
The only subgroup to have a significant benefit from CABG was 
the 245 subjects with left main and triple-vessel disease (HR, 
3.05 (CI, 1.29–7.21)).
Among patients with left main CAD, PCI was non-inferior 
to CABG. However, the point estimate appeared to be related 
to the number of vessels involved. Thus, to the extent that we 
can generalize these results to patients with kidney disease, who 
bear a greater burden of CAD, PCI should be considered a viable 
option with additional consideration among those patients with 
three-vessel and left main lesions.
Lynda Szczech 
